Enlivex Therapeutics Ltd [NASDAQ: ENLV] price plunged by -31.32 percent to reach at -$0.57.
A sum of 10361552 shares traded at recent session while its average daily volume was at 236.72K shares. Enlivex Therapeutics Ltd shares reached a high of $1.75 and dropped to a low of $1.22 until finishing in the latest session at $1.25.
The one-year ENLV stock forecast points to a potential upside of 90.38. The average equity rating for ENLV stock is currently 1.00, trading closer to a bullish pattern in the stock market.
Guru’s Opinion on Enlivex Therapeutics Ltd [ENLV]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for ENLV shares is $13.00 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on ENLV stock is a recommendation set at 1.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
H.C. Wainwright have made an estimate for Enlivex Therapeutics Ltd shares, keeping their opinion on the stock as Buy, with their previous recommendation back on March 02, 2021.
The Price to Book ratio for the last quarter was 1.45, with the Price to Cash per share for the same quarter was set at 0.87.
ENLV Stock Performance Analysis:
Enlivex Therapeutics Ltd [ENLV] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -14.97. With this latest performance, ENLV shares gained by 5.04% in over the last four-week period, additionally plugging by 19.05% over the last 6 months – not to mention a rise of 6.84% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for ENLV stock in for the last two-week period is set at 44.24, with the RSI for the last a single of trading hit 0.2296, and the three-weeks RSI is set at 0.1633 for Enlivex Therapeutics Ltd [ENLV]. The present Moving Average for the last 50 days of trading for this stock 1.2453, while it was recorded at 1.5960 for the last single week of trading, and 1.1276 for the last 200 days.
Enlivex Therapeutics Ltd (ENLV) Capital Structure & Debt Analysis
According to recent financial data for Enlivex Therapeutics Ltd. ( ENLV), the Return on Equity (ROE) stands at -60.35%, highlighting a negative impact on investor capital. The Return on Assets (ROA) is -52.02%, reflecting the company’s efficiency in generating profits from its assets. Additionally, Enlivex Therapeutics Ltd’s Return on Invested Capital (ROIC) is -68.57%, showcasing its effectiveness in deploying capital for earnings.
Enlivex Therapeutics Ltd (ENLV) Efficiency & Liquidity Metrics
Based on Enlivex Therapeutics Ltd’s (ENLV) latest financial statements, the Debt-to-Equity Ratio is 0.02%, indicating its reliance on debt financing relative to shareholder equity.
Enlivex Therapeutics Ltd (ENLV) Efficiency & Liquidity Metrics
From an operational efficiency perspective, Enlivex Therapeutics Ltd. (ENLV) effectively leverages its workforce, generating an average of -$398055.56 per employee. The company’s liquidity position is robust, with a Current Ratio of 7.20% and a Quick Ratio of 7.20%, indicating strong ability to cover short-term liabilities.
ENLV Stock EPS
With the latest financial reports released by the company, Enlivex Therapeutics Ltd posted -0.16/share EPS, while the average EPS was predicted by analysts to be reported at -0.08/share. When compared, the two values demonstrate that the company fail the estimates by a Surprise Factor of -0.08. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for ENLV. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Enlivex Therapeutics Ltd go to -6.46%.
Enlivex Therapeutics Ltd [ENLV] Institutonal Ownership Details
There are presently around $10.89%, or 11.42%% of ENLV stock, in the hands of institutional investors. The top three institutional holders of ENLV stocks are: ARMISTICE CAPITAL, LLC with ownership of 1.7 million shares, which is approximately 9.0808%. MORGAN STANLEY, holding 0.24 million shares of the stock with an approximate value of $$0.35 million in ENLV stocks shares; and MORGAN STANLEY, currently with $$0.1 million in ENLV stock with ownership which is approximately 0.3828%.
